Literature DB >> 11111308

[The quality of the drug treatment in hyperlipemia patients from 4 health areas. The VICAF Group].

T Sanz Cuesta1, E Escortell Mayor, M I Fernández San Martín, C López Bilbao, B Medina Bustillo, C Torres Bouza.   

Abstract

OBJECTIVE: To calculate how suitable the lipid-lowering treatment prescribed for pensioners in primary care clinics in four health areas is.
DESIGN: Cross-sectional descriptive study of quality of pharmacological treatment.
SETTING: Four primary care health districts, INSALUD, Madrid. PARTICIPANTS: 1125 patients registered with 49 doctors, chosen at random on the basis of three strata defined by the value of the lipid-lowering drug indicator of prescription. For a year, each doctor filled in a protocol of variables for each pensioner to whom he/she prescribed a lipid-lowering drug.
MEASUREMENTS AND MAIN RESULTS: An automated algorithm was designed to evaluate the suitability of the drugs treatment for each patient, according to scientific criteria including: cholesterol levels, LDL, age, and risk factors. Quality of prescription was finally measured for 1009 patients. The indication of the treatment was due to primary prevention in 65% of cases. 32% of patients were correctly treated. If LDL compliance was not demanded, the suitability figure rose to 77%. Drug treatment was more suitable when the doctor him/herself administered it (as against another doctor or a specialist; p = 0.001) or when the patient was on the list of the prescribing doctor (p < 0.0001). Proper indication was lower in patients over 74 (p < 0.0001).
CONCLUSIONS: The quality of lipid-lowering drug prescription for pensioners in primary care clinics in four health districts, as a function of the criteria defined above, could be improved. LDL is the factor which most affects the procedure.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11111308     DOI: 10.1016/s0212-6567(00)78685-9

Source DB:  PubMed          Journal:  Aten Primaria        ISSN: 0212-6567            Impact factor:   1.137


  2 in total

1.  The cost of inadequate prescriptions for hypolipidaemic drugs. VICAF Group.

Authors:  L C Ballesteros; M I Fernández San Martín; T Sanz Cuesta; E Escortell Mayor; C López Bilbao
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  [Validity of an indicator of the quality of pharmacological prescription in patients with hyperlipemia].

Authors:  M Fernández San Martín; C López Bilbao; E Escortell Mayor; T Sanz Cuesta; L Fidalgo García; C Rodríguez Escolar
Journal:  Aten Primaria       Date:  2001-03-31       Impact factor: 1.137

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.